EQS-News: CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
With uncertainty brimming, Cboe highlights Biogen Inc. (NASDAQ: BIIB) as a chart that may have piqued investor interest following positive clinical trial results for their new Alzheimers drug.
- With uncertainty brimming, Cboe highlights Biogen Inc. (NASDAQ: BIIB) as a chart that may have piqued investor interest following positive clinical trial results for their new Alzheimers drug.
- Cboe has compiled a list of earnings for investors to keep an eye on at the bottom of this report.
- Shares of Biogen skyrocketed on Sept. 22nd after the company announced positive clinical trial results for their Alzheimers drug lecanemab.
- These results have brought Biogen closer to a Federal Drug Agency (FDA) approved Alzheimers drug, a feat several biopharmaceutical companies are competing to achieve.